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Abstract
Background: We sought to determine the intra- and inter-radiation therapist reproducibility of
a previously established matching technique for daily verification and correction of isocenter
position relative to intraprostatic fiducial markers (FM).
Materials and methods: With the patient in the treatment position, anterior-posterior and left
lateral electronic images are acquired on an amorphous silicon flat panel electronic portal imaging
device. After each portal image is acquired, the therapist manually translates and aligns the fiducial
markers in the image to the marker contours on the digitally reconstructed radiograph. The
distances between the planned and actual isocenter location is displayed. In order to determine the
reproducibility of this technique, four therapists repeated and recorded this operation two
separate times on 20 previously acquired portal image datasets from two patients. The data were
analyzed to obtain the mean variability in the distances measured between and within observers.
Results: The mean and median intra-observer variability ranged from 0.4 to 0.7 mm and 0.3 to 0.6
mm respectively with a standard deviation of 0.4 to 1.0 mm. Inter-observer results were similar
with a mean variability of 0.9 mm, a median of 0.6 mm, and a standard deviation of 0.7 mm. When
using a 5 mm threshold, only 0.5% of treatments will undergo a table shift due to intra or inter-
observer error, increasing to an error rate of 2.4% if this threshold were reduced to 3 mm.
Conclusion: We have found high reproducibility with a previously established method for daily
verification and correction of isocenter position relative to prostatic fiducial markers using
electronic portal imaging.
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Introduction
Carcinoma of the prostate is the most common form of
cancer in men [1]. In 2005, 232,090 new cases of prostate
cancer and 30,350 prostate cancer deaths were projected
in the United States [1]. External beam radiotherapy con-
stitutes one of the mainstays of therapy for patients with
localized disease. Given the relatively small treatment
fields used with conformal and intensity-modulated radi-
otherapy, there is a greater need for accurate targeting and
daily localization of the prostate gland, a task is being per-
formed by radiation therapists/technologists.
The prostate is located between the bladder and the rec-
tum, and its position within the pelvis can change accord-
ing to the degree of fullness of the bladder and rectum.
Variations in bladder and rectal filling have been shown
to affect prostate position within the pelvis, to an extent
which may require field adjustments during the course of
radiotherapy [2]. Since the rectum tends to become pro-
gressively less distended during a course of pelvic radio-
therapy (mean decrease in diameter 1.5 cm), the
predominant prostate motion is in the posterior and infe-
rior direction. In one study, 11% of patients showed an
inferior shift of the prostate of more than 1 cm and 30%
showed a posterior shift of more than 1 cm [3]. Indeed,
this variation in position cannot be assessed with external
skin marks or bony landmarks, the standard approach
used by radiation therapists on a daily basis. Any motion
of the target relative to these landmarks limits the accuracy
of radiotherapy. A safety margin is therefore applied dur-
ing treatment planning to ensure correct irradiation of the
target in spite of this movement.
Portal x-ray imaging is a technique used to monitor the
accuracy of beam isocenter positioning relative to bony
landmarks or fiducial markers during radiotherapy. Since
the prostate is not visible on portal imaging, radiopaque
fiducial markers are surrogates for organ localization in
portal images [4]. As prostate motion is the major source
of error in radiation treatment delivery [5], some investi-
gators have recommended that radio-opaque markers be
placed in the prostate prior to the start of radiotherapy. In
our clinic, a previously described technique for daily elec-
tronic portal imaging device (EPID) visualization and
alignment to prostate fiducial markers has been imple-
mented to reduce inter-fractional set-up uncertainty, with
the eventual goal of safely reducing PTV margins and nor-
mal tissue dose [6]. In order to determine, in part, the tar-
geting error associated with this technique, we sought to
measure intra and inter-radiation therapist variability
using fiducial markers for daily set-up assessment and
adjustment of external radiation beam targeting.
Methods and materials
Fiducial marker placement under MRI-guidance
The patient subjects of this study were enrolled on an IRB
approved protocol after providing informed consent. The
primary objective of this protocol was to validate the accu-
racy and tolerability of a new device that allows for the
placement of needles and fiducial markers within the
prostate gland based upon MR images instead of standard
ultrasound images. The secondary objective was to gain
experience using fiducial markers for daily assessment and
adjustment of external radiation beam targeting as per-
formed by radiation therapists.
Four sterile gold fiducial markers (1.2 × 3 mm, Med Tec®
– NWMP, Iowa) are placed within the prostate under MRI
guidance one week before external beam radiotherapy in
patients with localized prostate cancer [7]. Markers are
placed at the prostate base, apex, and right and left mar-
gins at the level of the mid-gland. The patient returns four
to five days later for a treatment planning MRI and a treat-
ment planning non-contrast CT.
Treatment planning
Treatment planning MRI consists of a T2-weighted fast
spin echo (FSE) acquisition (3500/120 TR/TE) for ana-
tomic and tumor delineation, and a proton density 3D
True Fast Imaging with Steady State Precession imaging
(CE-TrueFISP – 4.7/2.4 TR/TE) for optimal marker visual-
ization. Both image sets are acquired in the same axial ori-
entation with 26 slices (3 mm thickness) and a field of
view of 20 × 20 cm. The images are then superimposed
and a reference MR image is created by identifying the
marker locations on the anatomic T2-weighted FSE
images.
Non-contrast treatment planning CT images are acquired
with 3 mm slice thickness and a field of view of 48 cm to
encompass the skin surface. For both MRI and CT treat-
ment planning image acquisitions, patients empty their
bladders and are positioned supine with no knee support
and their feet bound together. The reference MR images
are then rigidly co-registered to the CT images (AcQSim,
Philips Medical Systems, Netherlands) by identifying the
common fiducial marker locations. The clinical target vol-
ume (CTV), which most commonly comprises the pros-
tate gland, is defined on the co-registered reference MR
image. The seminal vesicles, the rectum, and the streaking
artifact from the fiducial markers are segmented on the CT
images. Note that bloom artifact from the fiducial markers
was similarly present on MR images.
A margin of 1.5 cm radial and 1 cm posterior is added to
the CTV to generate the PTV for the first phase of the treat-
ment. After 46Gy, the margin is reduced to 1 cm radial
and 0.7 cm posterior, consistent with standard of careRadiation Oncology 2006, 1:2 http://www.ro-journal.com/content/1/1/2
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without daily image verification [8]. The total dose deliv-
ered ranges from 70–74Gy. A treatment plan is generated
with a four-field technique to encompass the PTV with the
98–100% isodose. The radiation dose is prescribed to the
100% isodose. Digitally reconstructed radiographs
(DRRs) with the overlying MLC profile and fiducial
Illustration of software interface for manual matching of fiducial markers Figure 1
Illustration of software interface for manual matching of fiducial markers. Panels A and C show portal images (anterior-poste-
rior (AP) and left lateral (LLat) respectively, red MLC profile) with a superimposed diagram representing the treatment plan-
ning MLC (blue profile) relative to fiducial markers locations (yellow outline). The therapist has manually aligned the yellow 
marker outlines in the treatment planning diagram to the radiopaque markers in the portal image. Panels B and D (correspond-
ing to panels A and C, respectively), represent the magnitude of couch movement required for a match (arrow). Using a 
threshold of 5 mm, a longitudinal shift (inferiorly) of 9 mm was required.Radiation Oncology 2006, 1:2 http://www.ro-journal.com/content/1/1/2
Page 4 of 6
(page number not for citation purposes)
marker outlines are generated, electronically saved, and
printed for reference to the portal films acquired on the
first day of treatment.
Daily verification and correction of isocenter position
Isocenter placement relative to fiducial markers is verified
on a daily basis prior to radiation delivery using an EPID
on the linear accelerator (Clinac ® 21EX-Varian). With the
patient in the treatment position, anterior-posterior and
left lateral electronic images are acquired with an amor-
phous silicon (a-Si) flat panel EPID. A single portal image
exposure is acquired using the treatment field's MLC pro-
file and energy. The fiducial markers are clearly visible
using 5 and 7 monitor units (MU) for the AP and lateral
portal images respectively. This portal imaging dose is
included in the daily treatment dose delivery.
Treatment planning MLC profiles with the relative fiducial
marker outlines are sent to the Vision™ software (Varian)
for comparison with the daily portal images. We assign
the property of the marker outlines to "matching anat-
omy" and a field aperture is created. After each portal
image is acquired, the radiation therapist uses the Anatomy
Match function on the Review workspace in Vision™ to
manually translate and align the yellow reference fiducial
marker outlines to the radiopaque markers on the portal
image. (Figure 1) Note that the yellow outlines are larger
than the radiopaque markers due to streaking artifact on
CT images. For simplicity no rotation is permitted in this
alignment. The magnitude of the orthogonal vectors
which comprise the 2D sum vector distance between the
planned and actual marker location is then automatically
calculated and displayed for the x and y dimensions. In
our standard supine, head-first patient set-up, the x
dimension represents left-right in anterior-posterior (AP)
images and anterior-posterior in left lateral images. The y
dimension is the superior-inferior direction for all images.
If the distance is less than 5 mm, the treatment is deliv-
ered. Otherwise, the patient is repositioned and re-imaged
for verification until the distance is less than 5 mm. Radi-
ation therapists are responsible for documenting the shifts
on a standardized form. After gaining experience with the
first 83 consecutive treatments, the threshold for reposi-
tioning was reduced to 3 mm.
Study design- determination of intra and inter-therapist 
reproducibility
Datasets for 10 treatments (10 AP and 10 Left Lateral por-
tal images) in each of two patients were archived for this
study, for a total of 40 images. Radiation therapists famil-
iar with the daily verification technique were instructed to
manually align the fiducial markers and document the
two absolute orthogonal shift distances for all 40 images,
for a total of 80 measurements. Therapists were instructed
to perform this task independently. This exercise was
repeated, within one to two days, by each of the four ther-
apists. Data were tabulated, and the intra and inter-radia-
tion therapist variability was calculated with simple
descriptive statistics, including the mean, median, and
standard deviation of the data. The data were analyzed in
terms of absolute difference between any pair of align-
ments. Inter-radiation therapist variability analysis was
therefore based on 1920 data points, derived from 24
comparison datasets of 80 points each (6 comparisons for
each of 4 radiation therapists).
Results
The mean and median intra-observer error of the meas-
ured distance for the manual match were 0.4 and 0.3 mm
(SD 0.5 mm) for observer A, 0.7 and 0.4 mm (SD 0.9
mm) for observer B, 0.5 and 0.5 mm (SD 0.4 mm) for
observer C, and 0.9 and 0.6 mm (SD 1 mm) for observer
D. (Figure 2A) Inter-observer results were similar with a
mean error of 0.9 mm, a median of 0.6 mm, and a stand-
ard deviation of 0.7 mm. (Figure 2B) When using a 5 mm
threshold, only 0.5% of treatments would undergo a table
shift due solely to intra or inter-observer error in this
Intra-observer (A) and inter-observer (B) variability Figure 2
Intra-observer (A) and inter-observer (B) variability. Histo-
grams depict the distribution of magnitude differences withi-
nand between each therapist's measurements in the manual 
match technique.Radiation Oncology 2006, 1:2 http://www.ro-journal.com/content/1/1/2
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study. If this threshold were reduced to 3 mm, 2.4% of
table shifts would be due to observer error.
A very small but statistically significant difference was
found in observer variability between lateral and AP por-
tal image manual matches (AP mean 0.8 mm [CI 0.75–
0.84], LLAT mean 1 mm [CI 0.94–1.1], P < 0.01).
This technique has now been clinically applied in 166
consecutive treatments in 6 patients. For the first 83 treat-
ments, with a repositioning threshold of 5 mm, 30 treat-
ments required table shifts prior to radiation delivery
(36%). For the latter 83 treatments, with a threshold of 3
mm, 25 fractions required table shifts (30%). Approxi-
mately 5–10 minutes were dedicated to this verification
depending on the need to reposition the patient.
Discussion
With the advent of IMRT and highly conformal radiother-
apy, there is mounting incentive to improve daily set-up
and targeting accuracy of the prostate gland. Strategies to
date have focused on reducing inter-fractional set-up
error, and include alternative immobilization tech-
niques[9], daily portal verification of isocenter position
relative to bony landmarks [10], trans-abdominal ultra-
sound-based verification of prostate position relative to
CT treatment planning contours (B-mode Acquisition and
Targeting System -BAT®) [11], daily CT scans on the treat-
ment couch [12], cone-beam CT mounted on the treat-
ment gantry [13], and daily portal verification of fiducial
marker locations relative to isocenter position [6,14,15]
In this study, we investigated the inter and intra-radiation
therapist reproducibility in fiducial marker alignment
using the "manual match" technique herein described. To
our knowledge, there are no prior studies addressing this
question. A review of the literature found two papers
addressing intra and/or inter-user variability with trans-
abdominal ultrasound for daily prostate positioning
(BAT®). In Langen et al. [16], inter-user variability of the
BAT® system was investigated with eight users, including 4
radiation oncologists, 2 physicists, 1 urologist, and only 1
radiation therapist. A variability of greater than 2 mm was
found in 50%, and greater than 4 mm in 25% of cases.
Using the same system, Serago et al. [11] found inter-user
variability to be greater than 3 mm in approximately 10%
of measurements, and intra-user variability was greater
then 3 mm in approximately 5% of cases depending on
the orientation of shift. Limitations of the BAT® system
which may account for it's poor inter and intra-user repro-
ducibility include error in the initial CT and isocenter def-
inition of the BAT® test phantom, and uncertainties in the
CT definition of the prostate which translate directly into
a systematic uncertainty in the BAT® alignment [16].
Using the fiducial marker technique, we achieved superior
results with an observer variability of greater than 3 mm
observed in only 2.4% of cases. Furthermore, this was
found with four radiation therapists involved in the rou-
tine treatment of our patients. Another advantage of the
fiducial marker approach is that it is not dependent on the
location of the prostate gland relative to the pubic symph-
ysis [16] and is less dependent on patient size and weight
[17]. The variability we observed may in part be due to
uncertainty in the manual alignment as the marker out-
line is larger than the radiopaque marker visualized on the
portal image. Prior studies have shown that the markers
do not migrate significantly during a course of therapy,
and as such, are reliable surrogates to the position of the
prostate gland [18,19]. The technique does not require
specialized localization software or hardware modifica-
tions beyond standard portal image software. It permits
portal imaging to be limited to the treatment field for
daily localization, sparing surrounding normal tissues
from cumulative dose which would be delivered in alter-
native open field localization systems [19].
We have also found a very small (0.2 mm) but statistically
significant increase in variability with the lateral align-
ment compared to the AP alignment. Although this differ-
ence is not clinically significant and is smaller than the
pixel size of the EPID (0.8 mm), it may point to poorer
visualization of the fiducial markers on the lateral image,
or to greater difficulty in alignment due to rotation of the
prostate gland along this axis.
There are limitations of our study design. We did not
address the radiation therapist's accuracy in the actual
table shift at the second verification. There was also no
systematic assessment of time cost to this procedure on a
daily basis. Finally, the four radiation therapists had a rel-
atively short interval of one to two days between the two
measurements. A larger user error might have been found
by increasing this interval.
Despite our reported level of accuracy, we acknowledge
that intra- and inter-radiation therapist variability is not
the sole source of set-up error in this technique. For sim-
plicity, we have opted to ignore rotational errors in align-
ment at the inception of this trial. Others have introduced
a collimator rotation in the lateral treatment fields if the
required rotation angle exceeds 3 degrees [6]. Future work
will determine the need, feasibility and reproducibility of
such a correction, as well as an assessment of the impor-
tant impact of intra-fractional organ and patient motion.
This work will be necessary in order to determine whether
PTV margins can be safely reduced with this technique.
In conclusion, we have found high intra and inter-radia-
tion therapist reproducibility with a simple method forPublish with BioMed Central    and   every 
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daily verification and correction of isocenter position rel-
ative to fiducial markers using electronic portal imaging.
We believe this is an important first step toward an even-
tual goal of PTV reduction and safe dose escalation.
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